Total Payments
$922,724
2024 Payments
$265,981
Companies
16
Transactions
179
Medicare Patients
2,229
Medicare Billing
$273,476
Payment Breakdown by Category
Research$770,662 (83.5%)
Consulting$119,805 (13.0%)
Travel$15,559 (1.7%)
Other$11,850 (1.3%)
Food & Beverage$4,848 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $770,662 | 3 | 83.5% |
| Consulting Fee | $119,805 | 41 | 13.0% |
| Travel and Lodging | $15,559 | 50 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,850 | 3 | 1.3% |
| Food and Beverage | $4,848 | 82 | 0.5% |
Payments by Type
Research
$770,662
3 transactions
General
$152,062
176 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $768,162 | 2 | $0 (2024) |
| BeiGene USA, Inc. | $57,604 | 55 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $37,445 | 59 | $0 (2023) |
| Janssen Biotech, Inc. | $22,797 | 25 | $0 (2023) |
| BeiGene, Ltd. | $14,813 | 4 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $6,202 | 7 | $0 (2018) |
| BeiGene Switzerland GmbH | $4,096 | 5 | $0 (2024) |
| Amgen Inc. | $3,750 | 2 | $0 (2021) |
| Lilly USA, LLC | $3,600 | 1 | $0 (2023) |
| Gilead Sciences, Inc. | $2,707 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $265,981 | 22 | Eli Lilly and Company ($246,909) |
| 2023 | $573,998 | 32 | Eli Lilly and Company ($521,253) |
| 2022 | $26,824 | 45 | BeiGene USA, Inc. ($10,423) |
| 2021 | $10,152 | 9 | Pharmacyclics LLC, An AbbVie Company ($7,150) |
| 2020 | $7,250 | 5 | Pharmacyclics LLC, An AbbVie Company ($3,650) |
| 2019 | $6,188 | 16 | Pharmacyclics LLC, An AbbVie Company ($5,992) |
| 2018 | $23,521 | 31 | Janssen Biotech, Inc. ($13,762) |
| 2017 | $8,811 | 19 | Pharmacyclics LLC, An AbbVie Company ($8,811) |
All Payment Transactions
179 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,130.28 | General |
| 12/24/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,075.51 | General |
| 12/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: Oncology | ||||||
| 12/02/2024 | BeiGene Switzerland GmbH | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Oncology | ||||||
| 10/20/2024 | BeiGene Switzerland GmbH | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $277.47 | General |
| Category: Oncology | ||||||
| 10/20/2024 | BeiGene Switzerland GmbH | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $36.28 | General |
| Category: Oncology | ||||||
| 10/20/2024 | BeiGene Switzerland GmbH | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Oncology | ||||||
| 10/20/2024 | BeiGene Switzerland GmbH | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Oncology | ||||||
| 09/25/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $50.38 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $246,909.24 | Research |
| 09/04/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/03/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $45.22 | General |
| Category: Oncology | ||||||
| 06/13/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $616.20 | General |
| Category: Oncology | ||||||
| 06/13/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $190.13 | General |
| Category: Oncology | ||||||
| 06/13/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 06/13/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $41.64 | General |
| Category: Oncology | ||||||
| 04/10/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $114.98 | General |
| Category: Hematology | ||||||
| 03/28/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $619.77 | General |
| Category: Oncology | ||||||
| 03/28/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $446.20 | General |
| Category: Oncology | ||||||
| 03/28/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $154.34 | General |
| Category: Oncology | ||||||
| 03/28/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $109.01 | General |
| Category: Oncology | ||||||
| 01/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $124.18 | General |
| Category: ONC | ||||||
| 12/08/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $108.82 | General |
| Category: Oncology | ||||||
| 11/09/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $38.82 | General |
| Category: Oncology | ||||||
| 11/06/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $28.16 | General |
| Category: DIABETES CARE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PCYC-1127-CA | Pharmacyclics LLC, An AbbVie Company | $2,500 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 567 | 762 | $365,312 | $64,436 |
| 2022 | 8 | 484 | 774 | $327,907 | $60,811 |
| 2021 | 7 | 486 | 741 | $304,784 | $66,440 |
| 2020 | 8 | 692 | 1,104 | $346,497 | $81,789 |
Total Patients
2,229
Total Services
3,381
Medicare Billing
$273,476
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 157 | 186 | $135,748 | $21,830 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 168 | 222 | $91,191 | $16,855 | 18.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 50 | 50 | $44,292 | $7,629 | 17.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 34 | $24,896 | $3,922 | 15.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 49 | $19,947 | $3,521 | 17.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 54 | $15,012 | $3,469 | 23.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 31 | 87 | $13,485 | $3,464 | 25.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 17 | 20 | $7,980 | $1,427 | 17.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 18 | 18 | $5,058 | $1,253 | 24.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 42 | 42 | $7,703 | $1,068 | 13.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 139 | 189 | $134,617 | $22,580 | 16.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 164 | 198 | $78,944 | $15,158 | 19.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 35 | 110 | $30,580 | $6,721 | 22.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 42 | 42 | $36,318 | $6,651 | 18.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 38 | 163 | $25,265 | $5,355 | 21.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 26 | 28 | $7,868 | $1,738 | 22.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 14 | 17 | $6,783 | $1,186 | 17.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 12 | $4,832 | $1,010 | 20.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 15 | 15 | $2,700 | $412.45 | 15.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 164 | 235 | $141,951 | $28,790 | 20.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 192 | 250 | $84,150 | $19,458 | 23.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 25 | 103 | $28,634 | $6,362 | 22.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 30 | 30 | $22,084 | $4,859 | 22.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 45 | 62 | $16,242 | $4,414 | 27.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 12 | 43 | $6,665 | $1,431 | 21.5% |
About Dr. Jorge Castillo, MD
Dr. Jorge Castillo, MD is a Hematology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1689891129.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jorge Castillo, MD has received a total of $922,724 in payments from pharmaceutical and medical device companies, with $265,981 received in 2024. These payments were reported across 179 transactions from 16 companies. The most common payment nature is "" ($770,662).
As a Medicare-enrolled provider, Castillo has provided services to 2,229 Medicare beneficiaries, totaling 3,381 services with total Medicare billing of $273,476. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology
- Location Boston, MA
- Active Since 04/19/2007
- Last Updated 11/26/2013
- Taxonomy Code 207RH0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1689891129
Products in Payments
- BRUKINSA (Drug) $64,307
- IMBRUVICA (Drug) $38,007
- Imbruvica (Drug) $19,481
- Kyprolis (Drug) $3,750
- Tecartus (Drug) $2,583
- Ibrutinib (Drug) $2,500
- ENJAYMO (Biological) $255.78
- DARZALEX (Biological) $253.90
- CABLIVI (Biological) $146.55
- Trodelvy (Drug) $124.18
- ELITEK (Biological) $115.97
- UroLift (Device) $77.58
- FREESTYLE LIBRE 2 (Device) $76.82
- FREESTYLE LIBRE 3 (Device) $56.32
- VONJO (Drug) $54.99
- SARCLISA (Biological) $50.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Boston
Jacalyn Rosenblatt, M.d, M.D
Hematology — Payments: $1.6M
Hematology $1.6M
Dr. Edward Benz, Md, MD
Hematology — Payments: $746,999
Hematology $746,999
Andrew Evens, Do, Ms, DO, MS
Hematology — Payments: $339,696
Hematology $339,696
Dr. Caron Jacobson, Md, MD
Hematology — Payments: $294,282
Hematology $294,282
Lynn Bry, Md, MD
Hematology — Payments: $285,993
Hematology $285,993
Kenneth Miller, M.d, M.D
Hematology — Payments: $222,747
Hematology $222,747